Evidence map›Paper›PMID 34193044›Full record

ArticleBMC genomic data2021

Transcriptome signature of miRNA-26b KO mouse model suggests novel targets.

Emiel P C van der Vorst, Mario A A Pepe, Linsey J F Peters, Markus Haberbosch, Yvonne Jansen, Ronald Naumann, Georgios T Stathopoulos, Christian Weber, Kiril Bidzhekov

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in BMC genomic data, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Nonhematopoietic MicroRNA-26bArteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Emiel P C van der Vorst *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. Emiel.van_der_Vorst@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-5771-6278
Mario A A Pepe *Helmholtz Center Munich, Munich, Germany.
Linsey J F PetersInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Markus HaberboschInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Yvonne JansenInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Ronald NaumannMPI of Molecular Cell Biology and Genetics, Dresden, Germany.
Georgios T StathopoulosHelmholtz Center Munich, Munich, Germany.
Christian Weber *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Kiril Bidzhekov *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. Kiril.Bidzhekov@med.uni-muenchen.de.
Ludwig-Maximilians-Universität München · DEMaastricht University · NLHelmholtz Zentrum München · DEMax Planck Institute of Molecular Cell Biology and Genetics · DE

Funding

H2020 European Research Council AdG692511
6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. One of the miRNAs that has been shown to play a role in various pathologies like cancer, neurological disorders and cardiovascular diseases is miRNA-26b. However, these studies only demonstrated rather ambiguous associations without revealing a causal relationship. Therefore, the aim of this study is to establish and validate a mouse model which enables the elucidation of the exact role of miRNA-26b in various pathologies.

resultsA miRNA-26b-deficient mouse model was established using homologous recombination and validated using PCR. miRNA-26b-deficient mice did not show any physiological abnormalities and no effects on systemic lipid levels, blood parameters or tissue leukocytes. Using next generation sequencing, the gene expression patterns in miRNA-26b-deficient mice were analyzed and compared to wild type controls. This supported the already suggested role of miRNA-26b in cancer and neurological processes, but also revealed novel associations of miRNA-26b with thermogenesis and allergic reactions. In addition, detailed analysis identified several genes that seem to be highly regulated by miRNA-26b, which are linked to the same pathological conditions, further confirming the role of miRNA-26b in these pathologies and providing a strong validation of our mouse model.

conclusionsmiRNA-26b plays an important role in various pathologies, although causal relationships still have to be established. The described mouse model of miRNA-26b deficiency is a crucial first step towards the identification of the exact role of miRNA-26b in various diseases that could identify miRNA-26b as a promising novel diagnostic or even therapeutic target in a broad range of pathologies.

Indexed as

MicroRNAsNeoplasmsTranscriptomeAnimalsDisease Models, AnimalHigh-Throughput Nucleotide SequencingMiceRNA, MessengerMicroRNAsRNA, MessengerAllergic reactionsCancerCardiovascular diseaseKnock-out mouse modelMicroRNA-26bNeurological disordersNext generation sequencingThermogenesis

Identifiers

PMID34193044
PMCPMC8243710
OpenAlexW3175225922

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.